Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05932602 · ClinicalTrials.gov registry record
AVEIR DR Coverage With Evidence Development (CED) Study
A clinical trial of Bradycardia and Arrythmia, sponsored by Abbott Medical Devices.
- Recruiting
- Registry status
- 2,812
- Enrollment target
- 1
- Study location
NCT05932602: Recruiting study of Bradycardia and Arrythmia, sponsored by Abbott Medical Devices.
NCT05932602 is a study of Bradycardia and Arrythmia that is actively recruiting participants, run by Abbott Medical Devices. The registered enrollment target is 2,812 participants, below the 4,316-participant average among 29 other Bradycardia trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05932602, a study of Bradycardia and Arrythmia, is actively recruiting participants, sponsored by Abbott Medical Devices.
- RECRUITING
- Registry status
- 2,812 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this coverage with evidence development (CED) study is to evaluate complications and long-term health outcomes of the dual chamber Aveir Leadless Pacemaker device (aka Aveir™ DR LP system).
Primary Outcome
Assess the acute (30-day) complication rate of the Aveir DR LP, compared to dual chamber transvenous pacemakers. An acute complication is defined as a peri-procedural, device-related adverse event occurring within 30 days post-implant.
Conditions Studied
Interventions
- DEVICE Aveir DR Leadless Pacemaker System
- DEVICE Dual Chamber Transvenous Pacemaker
Study Locations (1)
California
- Abbott - Sylmar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,812 participants |
| Start Date | 2023-10-31 |
| Est. Completion | 2030-05 |
What NCT05932602 shows while recruiting
NCT05932602 is an observational study that tracks outcomes without assigning an intervention. Its 2,812 participants enrollment target places it among the larger protocols in the corpus, below the 4,316-participant average among 29 other Bradycardia trials with a reported enrollment target (35% lower).
The record links to 3 conditions, with Bradycardia appearing as the primary indexed condition, and to 2 interventions - of which Aveir DR Leadless Pacemaker System is the first listed.
NCT05932602 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05932602 about?
NCT05932602 is a clinical study titled "AVEIR DR Coverage With Evidence Development (CED) Study". The purpose of this coverage with evidence development (CED) study is to evaluate complications and long-term health outcomes of the dual chamber Aveir Leadless Pacemaker device (aka Aveir™ DR LP system).
What is the current status of trial NCT05932602?
This trial is currently recruiting. The enrollment target is 2,812 participants. The study started on 2023-10-31. Estimated completion is 2030-05.
What conditions does trial NCT05932602 study?
This clinical trial studies the following conditions: Bradycardia, Arrythmia, Cardiac Pacemaker.
What interventions are being tested in trial NCT05932602?
The interventions under investigation include: Aveir DR Leadless Pacemaker System (DEVICE), Dual Chamber Transvenous Pacemaker (DEVICE).
Who is sponsoring clinical trial NCT05932602?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05932602 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bradycardia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05932602's enrollment target sits among peer trials
2,812 8th of 29 higher than 22 of 29 other Bradycardia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bradycardia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effect of Womb Recordings on Maturation of Respiratory Control in Preterm Infants
RECRUITING · NA
-
Aveir VR Real-World Evidence Post-Approval Study
RECRUITING
-
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
RECRUITING
-
The Alaska Oculocardiac Reflex Study
RECRUITING
-
His Bundle Pacing in Bradycardia and Heart Failure
RECRUITING
-
Ultra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02273297 · 2,821 participants
Healthy Start: Exploring the Fuel-mediated Programming of Neonatal Growth
- NCT05443737 · 2,800 participants · Phase 3
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
- NCT05899439 · 2,800 participants
Immune Function and the Progression to T1D
- NCT06089109 · 2,800 participants · NA
Creating VIP Corps to Reduce Maternal Deaths
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI